DBV Technologies | DBVT - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
DBV Technologies USD 194.17M 124.33M 2025-12
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Galectin Therapeutics USD 25.6M 2.04M 2024-06
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03